Organovo to Present FXR314 Data at DDW2024

Organovo Holdings, Inc. (Nasdaq:ONVO), a biotechnology firm concentrating on innovative treatments for inflammatory bowel disease (IBD), including ulcerative colitis, has announced that it will present data on its leading clinical-stage drug, FXR314, during Digestive Disease Week 2024 (DDW2024). This event will take place in Washington, D.C., from May 18 to May 21, 2024.

The company's poster presentation, titled “Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel disease,” is scheduled for Saturday, May 18, 2024, at 12:30 EDT in the session “Translational application of intestinal stem cells and organoid models.”

Keith Murphy, Organovo’s Executive Chairman, expressed enthusiasm about the upcoming presentation, noting the significance of DDW2024 as one of the premier gatherings of gastrointestinal physicians in the United States. He highlighted the potential of FXR314 in combination therapy, which enhances its appeal for future partnerships, alongside its promise as a monotherapy.

Organovo is advancing its biotechnology efforts by creating drugs that show efficacy in three-dimensional (3D) human tissues, positioning these as candidates for further drug development. The company’s leading molecule, FXR314, is advancing towards Phase 2 clinical trials for inflammatory bowel disease, with possible uses in metabolic liver disease and oncology. The company employs proprietary technology to construct 3D human tissues that replicate critical aspects of native human tissue, such as composition, architecture, function, and disease characteristics.